Effect of the Histone Deacetylase (HDAC) Inhibitor Belinostat on the Expression of the Aryl Hydrocarbon Receptor and its Target Genes in Human Cell Cultures

Pub Date : 2022-04-22 DOI:10.1134/s1062360422020023

A. A. Akishina, R. O. Cherezov, Y. E. Vorontsova, O. B. Simonova

引用次数: 0

Abstract

Aryl hydrocarbon receptor (AHR) is a highly conserved ligand-dependent transcription factor, whose target genes play a key role in detoxification, regulation of developmental processes, maintenance of eukaryotic homeostasis, and metabolism of medicinal compounds. This study demonstrates for the first time an increase in the expression of the aryl hydrocarboxylic receptor gene and its target genes in human cell cultures after exposure to a histone deacetylase inhibitor (belinostat), which is currently being considered as a possible therapeutic agent for the treatment of various types of gliomas, including glioblastomas.

Abstract Image

查看原文

组蛋白去乙酰化酶(HDAC)抑制剂Belinostat对人细胞中芳烃受体及其靶基因表达的影响

摘要烃基受体(AHR)是一种高度保守的配体依赖性转录因子，其靶基因在解毒、调节发育过程、维持真核生物稳态和药物化合物代谢等方面发挥着关键作用。本研究首次证明，暴露于组蛋白去乙酰化酶抑制剂(belinostat)后，人类细胞培养物中芳基羟基羧酸受体基因及其靶基因的表达增加，该抑制剂目前被认为是治疗各种类型胶质瘤(包括胶质母细胞瘤)的可能治疗剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文